State of California—Health and Human Services Agency
California Department of Public Health

ADAP MM 2024-27

January 13, 2025

TO:

ADAP Enrollment Workers

SUBJECT:

Additions to the ADAP Formulary

Effective November 22, 2024, the following medications and ancillary device were added to the ADAP formulary:

bedaquiline
pretomanid
nirmatrelvir/ritonavir (Paxlovid)
norgestrel (Opill)
clomiphene
human chorionic gonadotropin (HCG) (added to the ADAP formulary effective 11/22/2024)
Aerochamber Flow-Vu Plus (added to ADAP formulary effective 12/04/2024)

Bedaquilineis a diarylquinoline antimycobacterial used in combination with other antibacterials to treat pulmonary multidrug-resistant tuberculosis (MDR-TB).

Pretomanid is a nitroimidazole antimycobacterial used in combination with other antibacterials to treat pulmonary MDR-TB. It is often used with bedaquiline and linezolid.

Nirmatrelvir/ritonavir (Paxlovid)is an oral antiviral medication used to treat COVID-19.

Opill (Norgestrel 0.075mg) is the first United States Food and Drug Administration (FDA) approved over-the-counter birth control pill. Daily oral contraception is safe and is more effective than other available nonprescription contraceptive methods (e.g., condoms). Opill may be an important option to reduce the number of unintended pregnancies, particularly for individuals who face barriers to healthcare access.

Clomipheneis an FDA-approved selective estrogen receptor modulator indicated to treat anovulatory or oligo-ovulatory infertility. Clomiphene may increase the chance of pregnancy for cisgender women with certain types of infertility.

Human chorionic gonadotropin is a hormone with a mechanism of action like pituitary luteinizing hormone. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone. In cisgender men, it can be used to treat selected cases of hypogonadism secondary to a pituitary deficiency. In cisgender women, it can be used to induce ovulation and pregnancy in select women who are infertile due to anovulation.

Aerochamber Plus Flow-Vu is an important medical device used in conjunction with inhalers to improve the delivery of medications to the lungs, particularly for individuals with asthma, chronic obstructive pulmonary disease, or other respiratory conditions.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary (PDF) has been updated to reflect the medications discussed above.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).

Thank you,

Joseph Lagrama Signature.png